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ABSTRACT
Argonaute (Ago) proteins are highly conserved
between species and constitute a direct-binding
platform for small RNAs including short-interfering
RNAs (siRNAs), microRNAs (miRNAs) and Piwi
interacting RNAs (piRNAs). Small RNAs function as
guides whereas Ago proteins are the actual medi-
ators of gene silencing. Although the major steps in
RNA-guided gene silencing have been elucidated,
not much is known about Ago-protein regulation.
Here we report a comprehensive analysis of Ago2
phosphorylation in human cells. We find that the
highly conserved tyrosine Y529, located in the
small RNA 50-end-binding pocket of Ago proteins
can be phosphorylated. By substituting Y529 with
a negatively charged glutamate (E) mimicking a
phosphorylated tyrosine, we show that small RNA
binding is strongly reduced. Our data suggest that
a negatively charged phospho-tyrosine generates a
repulsive force that prevents efficient binding of the
negatively charged 50 phosphate of the small RNA.
INTRODUCTION
Small non-coding RNAs such as miRNAs, endogenous
short-interfering RNAs (endo-siRNAs) or Piwi interacting
RNAs (piRNAs) form a speciﬁc class of non-coding
RNAs with distinct functions in post-transcriptional
gene regulation (1,2). MiRNAs are the best-characterized
class of small non-coding RNAs in mammals. MiRNA
genes are transcribed to primary miRNA transcripts
(pri-miRNAs), which are processed to stem-loop
structured miRNA precursors (pre-miRNAs). This
processing event involves the action of the nuclear micro-
processor complex containing the RNase III enzyme
Drosha. In the cytoplasm, pre-miRNAs are further
processed to short double-stranded (ds) RNA intermedi-
ates by the RNase III enzyme Dicer (3). After further
processing and unwinding steps, one strand is
incorporated into a miRNA–protein complex referred to
as miRNP or miRNA-containing RNA-induced silencing
complex (miRISC) (3). MiRNAs guide miRNPs to speciﬁc
sites typically located in the 30-untranslated region (UTR)
of target mRNAs. Imperfect pairing of the miRNA with
the target site leads to translational repression and/or
mRNA degradation resulting in an efﬁcient repression
of gene expression. In contrast, perfect or nearly perfect
pairing of a miRNA with its target RNA induces RNA
interference (RNAi)-like cleavage (4–6).
Members of the Argonaute protein family represent the
protein-binding partners of small RNAs (7). Argonaute
proteins are typically composed of three distinct
domains. The PAZ (Piwi–Argonaute–Zwille) domain
recognizes the characteristic 2-nt 30-overhangs generated
by RNase III enzymes such as Dicer and Drosha and
anchors the 30-end of small RNAs (8). The PIWI
(P-element-induced wimpy testes) domain folds similar
to RNase H and it has been shown for some Argonaute
proteins that the PIWI domain contains endonucleolytic
activity (8). A third domain, termed MID domain because
of its localization between the PAZ and the PIWI domain
anchors the 50-end of the small RNA (9,10). Thus,
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for functional small RNAs (11–13). Using RNAi reporter
systems as well as in vitro RNA cleavage assays, it has
been shown that Ago2 is the only member of the human
Ago protein sub-family that possesses endonucleolytic
cleavage activity although critical amino acids are
conserved in other human Ago proteins as well (14,15).
It is therefore still unclear what the exact functions of the
individual human Ago proteins are.
Ago proteins interact with a conserved protein family
generally referred to as the GW182 protein family (16–20).
GW182 proteins have initially been reported as integral
components of cytoplasmic processing bodies (P-bodies).
P-bodies are only poorly understood protein–RNA aggre-
gates that are enriched for enzymes that are important for
RNA metabolism (21). Later on, it has been demonstrated
that both miRNAs and Ago proteins localize to P-bodies
as well (17,19,22–24). GW182 proteins are characterized
by multiple glycine–tryptophan (GW) repeats that form
multiple Ago interaction modules termed ‘Ago hooks’
(25). In human, three different GW182 homologs termed
TNRC6A-C have been found (26). It has been
demonstrated in mammals as well as in Drosophila that
GW182 proteins interact with the poly(A)-binding protein
PABP (27,28), thereby interfering with translational
initiation (27).
To date, only little is known about how human small
RNA-guided gene-silencing pathways are regulated. A
number of post-translational modiﬁcations have been
reported that suggest regulation of Argonaute function.
Using mass spectrometry analysis, it has been found that
human Ago2 is hydroxylated at proline-700 and that this
post-translational modiﬁcation inﬂuences Ago stability
(29). Moreover, human Ago2 is phosphorylated at
serine-387 leading to altered cellular localization (30).
However, functional consequences of such phosphoryl-
ation events have not yet been reported. Therefore, we
analyzed phosphorylation of human Ago proteins in
detail and show that Ago proteins are phosphorylated
at multiple sites. We ﬁnd that Ago proteins are
phosphorylated at a tyrosine residue in the MID domain
that is critical for binding of the 50-end of the small RNA.
Furthermore, our data suggest that phosphorylation of
this tyrosine inhibits small RNA binding. Therefore, we
have identiﬁed a potential molecular switch that might
allow for loading and unloading of Ago proteins with
small RNAs.
MATERIALS AND METHODS
In vivo radiolabeling
HEK 293 cells grown on a 10cm dish in
DMEM-containing antibiotics but only 2% FBS were
transfected by the calcium phosphate procedure as
described before (31). Forty hours post-transfection,
cells were rinsed with TBS and grown for further 4 h in
the presence of 1.6mCi ortho-[
32P]-phosphate (Perkin
Elmer). Total lysates were generated in the presence of
sodium vanadate, a protein phosphotyrosyl phosphatase
inhibitor.
In vitro RISC assays and quantiﬁcation
Preparation of cap-
32P-labeled RNA used as RISC
substrate was described earlier (15). Assays were
performed with 50% (v/v) immunoprecipitated protein
coupled to anti-FLAG beads in a ﬁnal volume of 25ml
in the presence of 40mM KCl, 4mM Mg2Cl, 5mM
DTT, 1mM ATP, 0.2mM GTP and 1.2U RiboLock
RNase inhibitor (Fermentas). Cleavage reactions were
started by addition of the target RNA (1.0Bq/cm
2) and
incubated at 30 C for 60min. RNA extraction and
analysis has been described before (31).
For kinetic studies a multiple of a 25ml reaction was
prepared and incubated at 30 C. After the time points
indicated 25ml were removed and immediately subjected
to proteinase K digestion for subsequent RNA analysis by
denaturing gel electrophoresis, while another 25ml were
removed and added to denaturing protein sample buffer
for protein analysis. Signal intensities observed in the
radiograph were quantiﬁed using ImageGauge software
version 4.1 (Fuji). For each time point the intensities of
the cleavage product as well as the one of the whole lane
were determined and corrected for background. The
product/total ratio was plotted against time.
The sequence of the exogenous, chemically 50-modiﬁed
small RNA used in Figure 6D is UCGAAGUAUUCCGC
GUACGUdT. The small RNA was pre-incubated with
the immunoprecipitated proteins for 20min before the
radioactively labeled substrate RNA was added and the
RISC assay continued as described above.
In vitro Dicer assays
Pre-miR-27a was described before (32). In vitro transcrip-
tion was performed in the presence of [
32P]-UTP resulting
in internally labeled pre-miR-27a. Immunoprecipitated
proteins were incubated in a ﬁnal volume of 20ml in the
presence of 5mM ATP, 7.5mM MgCl2, 4 U RiboLock
RNase inhibitor (Fermentas) for 90min at 37 C. RNA
was phenol/chloroform extracted, ethanol precipitated
and analyzed by denaturing gel electrophoresis.
Northern blotting
Northern blotting was performed as described earlier (33).
Brieﬂy, RNA isolated from immunoprecipitations was ex-
tracted and solved in formamide loading dye, separated by
electrophoresis on 15% denaturing polyacrylamide gels
and transferred to Hybond-N membrane (Amersham
Bioscience) by semidry blotting. Membranes were dried,
UV treated and incubated for 1h at 80 C. After
pre-hybridization the 50-[
32P]-labeled probe was added
over night. Subsequently, the membrane was washed in
10min intervals twice with 5  SSC; 1% (w/v) SDS and
once with 1x SSC; 1% (w/v) SDS. Exposure to Kodak
BioMax MS ﬁlms (Kodak) was performed at  80 C
using an intensifying screen (GE Healthcare). Probe for
miR-19b: tcagttttgcatggatttgcaca; probe for miR-16:
cgccaatatttacgtgctgcta; probe for miR-25: tcagaccgaga-
caagtgcaatg; probe for 21.27: cgtacgcggaatacttcgat (34).
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and quantiﬁcation
Immunoprecipitates of FH-tagged proteins were halved
and subjected to RISC assembly in a total volume of
50ml under the same buffer conditions as speciﬁed for
the in vitro RISC assay. Either 1pmol of 50-P - 21.27
(=r(UCGAAGUAUUCCGCGUACGU)dT) or because
of a weaker blot efﬁciency 6pmol of 50-C H 3-21.27
single-stranded RNA were added to the immunopre-
cipitated proteins and incubated at 30 C for 30min.
Subsequently samples were washed twice with IP wash
buffer (50mM Tris–HCl, pH 7.5; 300mM NaCl; 5mM
MgCl2; and 0,05% Nonidet P-40) followed by PBS and
splitted again. One-half was subjected to protein analysis
by western blotting, the other half to RNA analysis by
northern blotting using a probe against siR-21.27 (34).
Signal intensities of two independent experiments were
determinded as described above and corrected for
background to ﬁnally plot the arithmetic mean against
sample identity.
Immunoprecipitation of phosphotyrosine proteins
Monoclonal anti-phosphotyrosine antibodies or monoclo-
nal anti-RMC antibodies were coupled to protein G
sepharose over night. The matrix was subsequently
incubated with 3mg BSA for 1 h and washed with PBS
before cytoplasmic extract from HEK 293 cells prepared
in the presence of 10mM sodium vanadat (inhibitor for
protein phosphotyrosyl phosphatases) was added. After 4
h of slow rotation at 4 C beads were washed three times
with IP wash buffer containing 1.2 M NaCl, twice with 0.6
M, once with PBS including 0.1% (v/v) Triton and ﬁnally
with PBS only.
cDNA synthesis and qRT-PCR
RNA was extracted from 5% (v/v) of the input (500ml)
and from 50% of the immunoprecipitates by proteinase K
digestion, phenol extraction and ethanol precipitation.
RNA was treated with DNase I in a total volume of
18ml for 30min at 37 C followed by heat inactivation
at 65 C. cDNA from 1ml was synthesized using the
ﬁrst-strand-cDNA synthesis kit (Fermentas) and the
random hexamers therein. Obtained cDNA was diluted
to 100ml and used for qRT-PCR, which was performed
in quadruplicates. For each reaction 6.7ml cDNA was
added to MESA GREEN qPCR MasterMix Plus for
SYBR Assay w/ﬂuorescein (Eurogentec) and 0.2mM
primer in a total volume of 15ml. Data were analyzed
according to the 2(-delta delta C(T))-method (35).
Gapdh was chosen for normalization.
RESULTS
Human Ago1 and Ago2 are phosphorylated in vivo
Many proteins are post-translationally modiﬁed.
Phosphorylation, for example, can occur on serine, threo-
nine and tyrosine side chains and is an important regula-
tory means for a wide range of human proteins. Therefore,
we analyzed Ago1 and Ago2 phosphorylation in HEK 293
cells. Myc-Ago1 and myc-Ago2 were transiently trans-
fected into HEK 293 cells followed by in vivo
32P
labeling (Figure 1A). After labeling, cell lysates were
generated and myc-Ago1/2 were immunoprecipitated
using anti-myc antibodies. Because of the instability of
protein phosphorylation, lysate preparation was carried
out in the presence of phosphatase inhibitors.
Immunoprecipitates were analyzed by autoradiography
(left panel) or western blotting (right panel). Indeed,
32P
was efﬁciently incorporated into myc-Ago1 as well as
myc-Ago2 indicative of protein phosphorylation. We
focused our further studies on Ago2 and analyzed
speciﬁc phosphorylation sites by mass spectrometry.
FLAG/HA-tagged Ago2 (FH-Ago2) was immunopre-
cipitated from HEK 293 cell lysates in the presence of
phosphatase inhibitors and subsequently digested by
trypsin. Digested peptides were enriched for
phosphopeptides using TiO2 afﬁnity puriﬁcation and
analyzed by nanoLC-ESI MS and MS/MS. We identiﬁed
ﬁve phosphopeptides, which are listed in Figure 1B. Of
note, phosphorylated serines (pS), threonines (pT) as
well as tyrosines (pY) were found. Since tyrosine phos-
phorylation was found at very intriguing positions, we
further validated our mass spec results, which were
obtained from tagged Ago proteins. To rule out that the
observed tyrosine phosphorylation resembles an Ago
overexpression artifact, we immunoprecipitated endogen-
ous proteins using an anti-phospho-tyrosine antibody and
analyzed the immunoprecipitate for the presence of
endogenous Ago2 by western blotting (Figure 1D).
Indeed, Ago2 was readily co-immunoprecipitated suggest-
ing that endogenous Ago2 is phosphorylated at the
indicated tyrosine residues. In summary, our results
demonstrate that human Ago2 is phosphorylated in vivo
at a number of different amino acid residues.
A highly conserved tyrosine located in the MID domain
can be phosphorylated
We next analyzed the phosphorylated peptides in more
detail (Figure 1C). We found three phosphorylated
amino acid residues located in the PAZ domain (pS253,
pT303, pT307), one in the PIWI domain (pS798), two
in the L2 linker region (pS387, pY393) and one in the
MID domain (pY529). The latter peptide 526-
TPVpYAEVK-533, is part of the pocket that has been
implicated in binding of the 50 phosphate of the small
RNA (9,10). Y529 is conserved not only in all other
human Argonaute proteins but also in all other species
that have been analyzed (Supplementary Figure S1,
peptide 4). Therefore, we hypothesized that phosphoryl-
ation of Y529 could be a general regulatory mechanism
for small RNA binding.
Ago2 Y529 mutants are functional and interact with
Dicer and TNRC6B
To analyze the function of Ago2 Y529 in detail, we
generated a number of different point mutants. It has
been suggested that the aromatic ring of Y529 contributes
to the binding of small RNAs by stacking interaction with
the base of the 50-terminal nucleotide of the small RNA
2332 Nucleic Acids Research, 2011,Vol.39, No. 6Figure 1. Human Ago1 and Ago2 can be phosphorylated in vivo.( A) Myc-Ago1/2 transfected HEK 293 cells were labeled with [
32P] and myc-Ago1
(lanes 1 and 4), myc-Ago2 (lanes 2 and 5) or myc-GST (lanes 3 and 6) were immunoprecipitated using anti-myc antibodies. Radio-labeled proteins
were visualized by autoradiography (left panel) and western blotting with anti-myc antibodies (right panel). (B) Phosphorylated Ago2 peptides
detected by mass spectrometry. (C) Schematic representation of phosphorylated amino acid side chains on Ago2. (D) Tyrosine phosphorylated
proteins were immunoprecipitated from HEK 293 lysate using the monoclonal anti-phospho-tyrosine antibody 4G10 (lane 2) or a control antibody
(lane 3). Lane 1 shows 0.5% of the protein input that was used for the immunoprecipitations. Proteins were analyzed by western blotting using an
anti-Ago2 antibody.
Nucleic Acids Research,2011, Vol.39, No. 6 2333(9,10). Furthermore, the hydroxyl group of Y529 forms a
hydrogen bond with an oxygen atom of the 50 phosphate.
Therefore, we generated an Ago2 Y529F mutant that can
perform stacking interaction with the ﬁrst base but cannot
be phosphorylated. To destroy stacking interaction as
well, we replaced Y529 by alanine (Y529A). We further
generated an Ago2 Y529Q mutant with a long aliphatic
side chain. Finally, we replaced Y529 by a glutamate
(Y529E). The Y529E mutant can neither form a
hydrogen bond with the 50 phosphate nor perform
stacking interaction with the base of the 50 terminal
nucleotide. Furthermore, by mutating Y529 to E we
placed a negatively charged side chain into the
50-end-binding pocket thereby generating a negatively
charged environment similar to a phosphorylated Y529.
Substitution of speciﬁc amino acids can induce major
structural changes followed by partial or complete unfold-
ing. Therefore, we analyzed functionality of the Ago2
Y529 mutants. It has been shown before, that
Ago proteins stably interact with Dicer. Therefore Dicer
activity can be co-immunoprecipitated using antibodies
against Ago proteins (Figure 2A) (17,36,37). We trans-
fected FH-Ago2, FH-Ago2 Y529 mutants as well as
FH-Dicer and immunoprecipitated the tagged proteins
using anti-FLAG antibodies. Immunoprecipitates were
incubated with
32P-labeled pre-miR-27a and Dicer
cleavage products were analyzed by RNA gel electrophor-
esis. As expected, FH-Ago2 and FH-Dicer immunopre-
cipitates Dicer activity efﬁciently (lanes 3 and 8).
Interestingly, all Ago2 Y529 mutants co-
immunoprecipitated Dicer activity as efﬁciently as wild
type (wt) Ago2 suggesting that the mutants are functional.
It has been reported, that Ago2 Y529 is important for
the interaction of Ago2 with TNRC6B (25). Therefore, we
analyzed binding of TNRC6B to the Ago2 Y529 mutants
that we have generated (Figure 2B). Myc-TNRC6B was
transfected together with FH-Ago2 or FH-Ago2 Y529
mutants into HEK 293 cells. Ago2 complexes were
immunoprecipitated using anti-FLAG antibodies and
the immunoprecipitates were analyzed for the presence
of myc-TNRC6B by anti-myc western blotting. Indeed,
not only FH-Ago2 but also all Ago2 Y529 mutants
interacted with myc-TNRC6B suggesting that Y529 is
dispensable for interaction with TNRC6B.
Since miRNAs function as guides and Ago proteins
artiﬁcially tethered to mRNAs repress gene expression
(38), all Ago mutants were analyzed in tethering experi-
ments using the N–box B system (Figure 2C) (39).
Consistently with the interaction data, tethered wt Ago2
as well as all mutants inhibited luciferase expression. Of
note, the PAZ9 mutant that does not bind to small RNAs
(23) can still repress luciferase expression when artiﬁcially
tethered. These results further strengthen the assumption
that the individual Ago2 Y529 mutants are functional and
can be used for further analysis.
Strongly reduced P-body localization of Ago2 Y529E
It has been demonstrated before that Ago proteins as well
as miRNAs localize to cytoplasmic P-bodies
(17,19,22–24). We therefore analyzed sub-cellular
localization of wt as well as Ago2 Y529 mutants
(Figure 3). FH-Ago2 (panels 1–4), FH-Ago2 Y529F
(panels 5–8), FH-Ago2 Y529A (panels 9–12) and
FH-Ago2 Y529E (panels 13–16) were transfected and
ﬁxed cells were stained with antibodies against the
HA-tag and LSm4, which served as P-body marker. Wt
Ago2, the Ago2 Y529F and Ago2 Y529A mutants
localized to P-bodies. However, the Ago2 Y529E mutant
localized mainly to the diffuse cytoplasm and only a
strongly reduced co-staining with the P-Body marker
LSm4 was observed (Figure 3A and B). Our data
suggest that Y529 itself is not required for P-body local-
ization. However, the generation of a negatively charged
environment in the 50-end-binding pocket by substituting
Y529 with E severely impairs P-body localization of Ago2.
Mutation of Ago2 Y529 to E interferes with slicer
activity in vitro and in vivo
Ago2 is the only protein of the human Ago protein
sub-family that cleaves target RNAs with perfect comple-
mentarity to the bound small RNA (14,31). Consequently,
we analyzed the contribution of Y529 to the cleavage
activity of Ago2 (Figure 4). FH-Ago2 as well as the
FH-Ago2 Y529F, E and A mutants were transfected
and immunoprecipitated using anti-FLAG antibodies.
Isolated Ago complexes were incubated with a [
32P]-
cap-labeled target RNA complementary to endogenous
miR-19b. Speciﬁc cleavage products were analyzed by
denaturing RNA-gel electrophoresis (Figure 4A). Both
the Y529F and A mutants cleaved the target RNA,
although the cleavage activity was reduced compared to
wt Ago2. Strikingly, the Y529E mutant showed very little
cleavage activity indicating that carrying a negative charge
in the 50-end-binding pocket is incompatible with Ago2
slicer function in vitro. Time course experiments of wt
Ago2 as well as the individual mutants revealed compar-
able results to the end-point measurements shown in
Figure 4A (Figure 4B).
Next, slicer activity was analyzed in vivo (Figure 4C and
D). SiRNAs directed against the 30-UTR of Ago2 were
designed and used to knock down endogenous Ago2.
Following Ago2 knockdown, HeLa cells were transfected
with a reporter plasmid containing a cleavage site perfectly
complementary to endogenous miR-21 within the 30-UTR
of ﬁreﬂy luciferase. As expected, relative ﬁreﬂy luciferase
activity was elevated when Ago2 had been depleted. We
then performed rescue experiments by co-transfecting
siRNA-resistant wt Ago2 as well as the individual Ago2
Y529 mutants along with the reporter. Consistently with
the in vitro data, wt Ago2 and Ago2 Y529F rescued
silencing of the luciferase reporter (Figure 4D), while
Ago2 Y529E did not reverse the Ago2 knockdown
phenotype indicating that the Y529E mutant is cleavage
incompetent in vivo as well.
In mammals, most miRNAs target only partially
complementary sites and Ago2 contributes to translation-
al repression as well as deadenylation-dependent mRNA
decay. Therefore, we analyzed the interactions of wt Ago2
and the Ago2 Y529 mutants with an endogenous mRNA
target. We have found that Rap1a expression is regulated
2334 Nucleic Acids Research, 2011,Vol.39, No. 6Figure 2. Ago2 Y529 point mutants are functional. (A)[
32P]-labeled pre-miR-27a was incubated with immunoprecipitated FH-Ago2 (lane 3),
FH-Ago2 Y529A (lane 4), FH-Ago2 Y529E (lane 5), FH-Ago2 Y529F (lane 6), FH-Ago2 Y529Q (lane 7), FH-Dicer (lane 8), FH-PABPC1
(lane 9) or untransfected HEK 293 lysate (lane 10). Cleavage products were analyzed by denaturing RNA PAGE. Lane 1 shows a radio-labeled
size marker. Lanes 11–18 show anti-HA western blots of the protein input. (B) Myc-TNRC6B was co-transfected with FH-Ago2 (lanes 2 and 8),
FH-Ago2 Y529F (lanes 3 and 9), FH-Ago2 Y529E (lanes 4 and 10), FH-Ago2 Y529A (lanes 5 and 11) and FH-Ago2 Y529Q (lanes 6 and 12).
Immunoprecipitation using anti-FLAG antibodies was performed and co-immunoprecipitated proteins were analyzed by western blotting against the
myc-tag (left panel). The anti-HA western blot of the immunoprecipitates is shown to the right. In lanes 1 and 7, HEK 293 cell lysates containing
only myc-TNRC6B were used. (C) Tethering experiments. Ago2, Ago2 Y529F, Ago2 Y529A, Ago2 Y529E, Ago2 Y529Q, Ago2 PAZ9 and FMRP
as well as the empty plasmids as controls, all either N-HA-(white bars) or only HA-conjugated (grey bars) were co-expressed with a renilla luciferase
reporter that contained several boxB sites in its 30-UTR. Proteins were tethered to the reporter by the N-tag. Expression levels have been normalized
to co-transfected ﬁreﬂy luciferase. For analysis data were normalized to the individual untethered controls.
Nucleic Acids Research,2011, Vol.39, No. 6 2335by miR-19b in HEK cells (unpublished data) and this
regulation requires stable interaction with Ago2-miR-
19b complexes. FH-Ago2, FH-Ago2 Y529F, FH-Ago2
Y529A and FH-Ago2 Y529E constructs were transfected
into HEK 293 cells and proteins were immunoprecipitated
using anti-FLAG antibodies. The co-immunoprecipitated
mRNAs were extracted and analyzed by qRT-PCR for
enrichment of Rap1a after immunoprecipitation
(Figure 4E). As expected, wt-Ago2 co-immunoprecipitates
the Rap1a mRNA and similar effects were observed for
Figure 3. Cellular localization of Ago2 Y529 mutants. (A) FH-Ago2 (panels 1–4), FH-Ago2 Y529F (panels 5–8), FH-Ago2 Y529A (panels 9–12),
FH-Ago2 Y529E (panels 13–16) were transfected into HEK 293 cells. Cells were stained with anti-HA antibodies (panels 1, 5, 9, 13) and antibodies
against LSm4 (panels 2, 6, 10, 14). In panels 17–20, only the secondary antibody was used. Bars represent 10mm. (B) Quantiﬁcation of Ago2- or
Ago2 Y529 mutant-positive P-bodies relative to the total number of counted P-bodies.
2336 Nucleic Acids Research, 2011,Vol.39, No. 6Figure 4. Cleavage activity of Ago2 Y529 mutants. (A) FH-Ago1 (lane 2) as negative control, FH-Ago2 (lane 3), FH-Ago2 Y529F (lane 4),
FH-Ago2 Y529E (lane 5) and FH-Ago2 Y529A (lane 6) were immunoprecipitated from HEK 293 cell lysate and incubated with a [
32P]-cap-labeled
target RNA containing a perfect complementary target site for miR-19b. Speciﬁc cleavage products were analyzed by denaturing RNA PAGE. T1
indicates a partial nuclease T1 digestion of the target RNA (lane 1). The black bar to the left indicates the target site of miR-19b. (B) Kinetic analysis
of Ago2 and Ago2-Y529 mutant-cleavage activity. Non-saturated radioactive signals were quantiﬁed using the ImageGauge software. (C) SiRNAs
directed against the 30-UTR of endogenous Ago2 were transfected into HeLa cells (lane 1) and knockdowns were analyzed by western blotting using
anti-Ago2 (upper panel) or anti-actin antibodies (lower panel). (D) SiRNAs against the 30-UTR of Ago2 (grey bars) or control siRNAs (white bar)
were transfected into HeLa cells. After 48 h, knockdowns were rescued by transfecting wt Ago2, Ago2 Y529F, Ago2 Y529E or the empty plasmid
together with a ﬁreﬂy luciferase reporter containing a perfectly complementary target site for endogenous miR-21. After 2 days, luciferase activity
was measured. Fireﬂy luciferase activity was normalized to renilla luciferase activity and the obtained values were normalized to the control without
Ago2 knockdown (upper panel). Representative protein levels analyzed by anti-HA western blotting are shown in the lower panel. (E) FH-tagged
Ago2 as well as the Ago2-Y529F, Ago2-Y529A and Ago2-Y529E mutants were immunoprecipitated from HEK 293 cell lysates using anti-FLAG
antibodies. The co-immunoprecipitated miR-19b target Rap1a was analyzed by qRT-PCR for enrichment in the precipitates (left panel). Protein
inputs that were used for the experiment are shown on the right.
Nucleic Acids Research,2011, Vol.39, No. 6 2337the Y529F and Y529A mutants. However, the Ago2
Y529E mutant cannot interact with the endogenous
mRNA target indicating that not only cleavage activity,
but also mRNA interaction is impaired when a negatively
charged environment is generated within the 50 phosphate
binding pocket of Ago2.
A negative charge in the 50-end-binding pocket mimicking
a phospho-tyrosine impairs small RNA binding
Based on the structure of the Archaeoglobus fulgidus Ago
protein that contains the conserved tyrosine at position
123 we modeled a phospho-tyrosine into the 50-end-
binding pocket (Figure 5A). A phospho-tyrosine not
only sterically interferes with the correct positioning of
the 50 phosphate of the small RNA but also repulses the
negative charge of the small RNA’s 50 phosphate (middle
panel). According to the modeled structure, the Y529E
mutant does not sterically hinder 50 phosphate binding
but its negative charge generates a repulsive force
against the negatively charged 50 phosphate of the small
RNA (lower panel). Therefore, the effects observed with
the Y529E mutant probably underestimate effects caused
by pY529.
The clear modeling data let to the conclusion that a
small RNA carrying a 50 phosphate can not efﬁciently
interact with the 50-end-binding pocket that contains a
pY529 or 529E. Therefore, we analyzed direct miRNA
binding to wt Ago2 or the individual Y529 mutants by
northern blotting (Figure 5B). FH-Ago2 as well as the
individual mutants were transfected into HEK 293 cells.
Ago2 proteins were immunoprecipitated with anti-FLAG
antibodies, associated RNA was extracted and analyzed
by northern blotting using probes complementary to
endogenous miR-19b (upper panel), miR-16 (middle
panel) or miR-25 (lower panel). Wt Ago2 as well as
Ago2 Y529F, Y529A and Y529Q efﬁciently
co-immunoprecipitated the analyzed miRNAs. In agree-
ment with the modeling data, Ago2 Y529E
co-immunoprecipitated miRNAs only marginally.
Taken together, our data suggest that a negatively
charged amino acid mimicking a phosphorylated
tyrosine in the 50 phosphate-binding pocket inhibits
small RNA binding and as a consequence cleavage
activity and P-body localization.
Ago2 Y529E interacts with 50 methylated single stranded
siRNAs
In order to further characterize the functional conse-
quences of a negative charge within the 50 end-binding
pocket, we hypothesized that a small RNA without a
50 phosphate should bind equally well to all Y529
mutants. We have demonstrated before that 50 methylated
single-stranded siRNAs are efﬁciently incorporated into
RISC (34). FH-Ago2, FH-Ago2 Y529F, FH-Ago2
Y529A and FH-Ago2 Y529E were immunoprecipitated
from HEK 293 cell lysates and incubated with 50
methylated or 50 phosphorylated single-stranded siRNAs
(Figure 6A, left and right panels). Of note, single stranded
siRNAs interact with wt Ago2 more efﬁciently compared
to endogenous miRNAs, which binds equally well to
the FH-Ago2 Y529F and FH-Ago2 Y529A mutants
(Figure 5B). However, when comparing the FH-Ago2
Y529F and FH-Ago2 Y529E mutants we ﬁnd no differ-
ence in binding when the 50 methylated siRNA was
used (Figure 6B, left panel). Binding of the 50
phosphorylated siRNA to FH-Ago2 Y529E was
Figure 4. Continued.
2338 Nucleic Acids Research, 2011,Vol.39, No. 6signiﬁcantly reduced (right panel), indicating that the
FH-Ago2 Y529E mutant indeed generates a negatively
charged environment that repulses the negatively
charged 50 phosphate of the siRNA. The protein input is
shown in Figure 6C.
To further analyze the activity of the Ago2 mutants
carrying 50 phosphorylated or methylated single-stranded
siRNAs, we performed in vitro cleavage assays
(Figure 6D). FH-Ago2, FH-Ago2 Y529F, FH-Ago2
Y529E as well as FH-Ago2 Y529A were expressed in
Figure 5. Small RNA binding of Ago2 Y529E is strongly reduced. (A) Structure modeling of Archaeoglobus fulgidus Ago. Y123 was replaced by
phospho-Y123 (panel 2) or E123 (panel 3). (B) FH-Ago2 (lane 3), FH-Ago2 Y529F (lane 4), FH-Ago2 Y529E (lane 5), FH-Ago2 Y529A (lane 6),
FH-Ago2 Y529Q (lane 7) and FH-PABPC1 as negative control (lane 8) were transfected into HEK 293 cells and immunoprecipitated using
anti-FLAG antibodies. Co-immunoprecipitated RNA was extracted and analyzed by northern blotting using probes speciﬁc to miR-19b (upper
panel), miR-16 (middle panel) or miR-25 (lower panel). In lane 2, untransfected cell lysate was used for immunoprecipitation. Lane 1: 30mg total
RNA from HEK 293 cells was blotted. Lanes 9-14: anti-HA western blot of the immunoprecipitates used for RNA extraction.
Nucleic Acids Research,2011, Vol.39, No. 6 2339HEK 293 cells and isolated by anti-FLAG immunopre-
cipitation. The isolates were incubated with a 50
phosphorylated or a 50 methylated siRNA strand. After
incubation a radio-labeled target RNA was added to the
reaction and the cleavage products were analyzed by RNA
PAGE. Consistently, with the small RNA-binding results
shown in Figure 6A/B, the FH-Ago2 Y529E mutant
showed very low-cleavage activity when loaded with a 50
phosphorylated siRNA compared to FH-Ago2 Y529F.
However, the cleavage activities of FH-Ago2 Y529F and
Figure 6. Ago2 Y529 mutants bind 50 methylated small RNAs equally well. (A) FH-PABPC1 (lanes 1 and 9) as an RNA-binding protein negative
control, FH-Ago2 (lanes 2 and 10), FH-Ago2 Y529F (lanes 3 and 11), FH-Ago2 Y529A (lanes 4 and 12), FH-Ago2 Y529E (lanes 5 and 13) and
FH-GFP as an unrelated negative control (lanes 6 and 14) were immunoprecipitated from HEK 293 cell lysates using anti-FLAG antibodies. Either a
50 methylated (left panel) or 50 phosphorylated (right panel) 21-nt single-stranded RNA was incorporated into the proteins. As control for unspeciﬁc
degradation, PBS only was used (lanes 8 and 16). Tagged proteins were puriﬁed by immunoprecipitation and bound RNA was extracted for analysis
by northern blotting using a probe speciﬁc to siR-21.27. (B) Quantiﬁcation of the northern blot signals observed for Ago2 Y529F and Ago2 Y529E
with a 50 methylated (left panel) and a 50 phosphorylated (right panel) 21-nt single-stranded RNA. Data used derive from two independent experi-
ments. (C) Protein inputs that were used for the experiment shown in (A). (D) FH-Ago1 (lanes 2 and 10), FH-Ago2 (lanes 3 and 11), FH-Ago2
Y529F (lanes 4 and 12), FH-Ago2 Y529E (lanes 5 and 13), FH-Ago2 Y529A (lanes 6 and 14) were immunoprecipitated using anti-FLAG antibodies
and subsequently incubated with a single stranded 50 phosphorylated (lanes 2–8) or a 50 methylated siRNA (lanes 10–16). After incubation a target
RNA was added to each sample carrying a binding site of perfect complementarity to the siRNAs used. Cleavage products were analyzed by
denaturing RNA PAGE. A western blot indicating the protein inputs is shown on the lower part of the ﬁgure.
2340 Nucleic Acids Research, 2011,Vol.39, No. 6FH-Ago2 Y529E were comparable when loaded with a
50-methylated siRNA indicating that the FH-Ago2
Y529E mutant is generally active but cannot load a
small RNA with a negatively charged phosphate group
on its 50-end.
DISCUSSION
Argonaute proteins are highly specialized binding modules
for small RNAs and mediators of small RNA-guided gene
silencing. However, not much is known about their regu-
lation. Here, we found that human Ago proteins are
Figure 6. Continued.
Nucleic Acids Research,2011, Vol.39, No. 6 2341phosphorylated at a number of different amino acids.
Most importantly, one speciﬁc tyrosine, namely Y529 in
human Ago2, located in the small RNA 50-end-binding
pocket of the MID domain can be phosphorylated
in vivo. Of note, the amount of Ago2 phosphorylated on
Y529 appears rather low in our experiments. However, we
cannot exclude that this is due to experimental or technical
reasons. Based on structural studies performed on
archaeal or bacterial Ago proteins, it is known that this
highly conserved tyrosine is located in close proximity to
the 50 phosphate of the small RNA that is generated by
cleavage of long dsRNA precursors by the RNase
III enzyme Dicer (9–12,40). Using structural modeling as
well as a number of biochemical approaches, we found
that placing a negative charge in position of the tyrosine
side chain does not allow for binding of the 50 phosphate
of the small RNA. The phospho-tyrosine sterically hinders
the docking of a second phosphate and the negative
charge generates a repulsive force against another
negatively charged group. Therefore, phosphorylation of
the highly conserved tyrosine Ago2-Y529 within the
50-end-binding pocket of the MID domain might
function as a molecular switch that promotes or inhibits
small RNA binding to Argonaute proteins.
Phosphorylation of Ago2 Y529 may have a number of
biologically important implications. Speciﬁc kinases and
phosphatases could turn Ago proteins on and off depend-
ing on cellular conditions such as stress-induced signaling,
differentiation or cell-cycle regulation. Our future work
clearly aims at the identiﬁcation of signaling pathways
that inﬂuence Ago phosphorylation under various
cellular conditions. Interestingly, it has been suggested
recently that Ago2 expression is controlled through
MAP kinase (MAPK) signaling (41). The stability of
Ago2 is inﬂuenced by the epidermal growth factor
receptor (EGFR) as part of the MAPK pathway. The
mechanistic details as well as the functional consequences
behind this observation, however, remain elusive. It has
further been reported before that Ago2 is phosphorylated
at serine 387 and it has been shown that the p38
MAP-kinase pathway is required for this modiﬁcation.
Phosphorylation at S387 inﬂuences P-body localization
of Ago2 and might serve as cellular regulator for Ago2
(30). It is becoming more and more apparent that
phosphorylation of Ago proteins is a common means for
regulating the activity of small RNA pathways. Detailed
knowledge of such modiﬁcations may also help to better
understand a number of diseases with abnormalities in
miRNA function or may also help to improve RNAi for
therapeutic applications.
Phosphorylation sites are typically located on the
surface of proteins allowing for efﬁcient accession of
kinases and phosphatases. However, Ago2 Y529 is
located in the 50-end-binding pocket of the MID domain
and not on the surface of Ago2. Three scenarios of how
Y529 might be phosphorylated could be envisioned. First,
highly specialized kinases or phosphatases that reach
Y529 within the 50-end-binding pocket for phosphoryl-
ation or de-phosphorylation could be responsible for the
observed modiﬁcation. Second, Ago proteins could
undergo conformational changes leading to a relocation
of Y529 to the protein surface, where Y529 would be more
accessible for kinases or phosphatases. Different struc-
tural studies on the same Ago protein from Aquifex
aeolicus suggest that the Ago structure is at least to
some extend ﬂexible (40,42,43). Third and most provoca-
tively, the 50 phosphate of the small RNA might be
transferred directly to Ago2 Y529. Structural modeling
studies (Figure 5A) suggest that the 50 phosphate is
positioned in close proximity to Y529. The biological con-
sequences of such a transfer mechanism remains elusive. It
is conceivable that phosphate transfer might occur during
RISC turn over and Y529 phosphorylated Ago2 resembles
a RISC break down intermediate. More functional experi-
ments will be needed to clearly identify the biological
function of Y529 phosphorylation of human Ago2.
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